160 related articles for article (PubMed ID: 35526235)
1. Does difference between label and actual potency of factor VIII concentrate affect pharmacokinetic-guided dosing of replacement therapy in haemophilia A?
Goedhart TMHJ; Bukkems LH; van Moort I; Spence CC; Zwaan MC; de Maat MPM; Mathôt RAA; Cnossen MH;
Haemophilia; 2022 Jul; 28(4):610-618. PubMed ID: 35526235
[TBL] [Abstract][Full Text] [Related]
2. The "OPTI-CLOT" trial. A randomised controlled trial on periOperative PharmacokineTIc-guided dosing of CLOTting factor concentrate in haemophilia A.
Hazendonk HC; van Moort I; Fijnvandraat K; Kruip MJ; Laros-van Gorkom BA; van der Meer FJ; Meijer K; Peters M; Schutgens RE; Zwaan CM; Driessens MH; Polinder S; Leebeek FW; Mathôt RA; Cnossen MH
Thromb Haemost; 2015 Aug; 114(3):639-44. PubMed ID: 26062822
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes of low-dose pharmacokinetic-guided extended half-life versus low-dose standard half-life factor VIII concentrate prophylaxis in haemophilia A patients.
Rakmanotham A; Moonla C; Sosothikul D
Haemophilia; 2023 Jan; 29(1):156-164. PubMed ID: 36409282
[TBL] [Abstract][Full Text] [Related]
4. Peri-operative desmopressin combined with pharmacokinetic-guided factor VIII concentrate in non-severe haemophilia A patients.
Romano LGR; Schütte LM; van Hest RM; Meijer K; Laros-van Gorkom BAP; Nieuwenhuizen L; Eikenboom J; Heubel-Moenen FCJI; Uitslager N; Coppens M; Fijnvandraat K; Driessens MHE; Polinder S; Cnossen MH; Leebeek FWG; Mathôt RAA; Kruip MJHA;
Haemophilia; 2024 Mar; 30(2):355-366. PubMed ID: 38343113
[TBL] [Abstract][Full Text] [Related]
5. Cross-evaluation of Pharmacokinetic-Guided Dosing Tools for Factor VIII.
Preijers T; van Moort I; Fijnvandraat K; Leebeek FWG; Cnossen MH; Mathôt RAA;
Thromb Haemost; 2018 Mar; 118(3):514-525. PubMed ID: 29534249
[TBL] [Abstract][Full Text] [Related]
6. Desmopressin treatment combined with clotting factor VIII concentrates in patients with non-severe haemophilia A: protocol for a multicentre single-armed trial, the DAVID study.
Schütte LM; Cnossen MH; van Hest RM; Driessens MHE; Fijnvandraat K; Polinder S; Beckers EAM; Coppens M; Eikenboom J; Laros-van Gorkom BAP; Meijer K; Nieuwenhuizen L; Mauser-Bunschoten EP; Leebeek FWG; Mathôt RAA; Kruip MJHA
BMJ Open; 2019 Apr; 9(4):e022719. PubMed ID: 31015264
[TBL] [Abstract][Full Text] [Related]
7. Perioperative pharmacokinetic-guided factor VIII concentrate dosing in haemophilia (OPTI-CLOT trial): an open-label, multicentre, randomised, controlled trial.
van Moort I; Preijers T; Bukkems LH; Hazendonk HCAM; van der Bom JG; Laros-van Gorkom BAP; Beckers EAM; Nieuwenhuizen L; van der Meer FJM; Ypma P; Coppens M; Fijnvandraat K; Schutgens REG; Meijer K; Leebeek FWG; Mathôt RAA; Cnossen MH;
Lancet Haematol; 2021 Jul; 8(7):e492-e502. PubMed ID: 34171280
[TBL] [Abstract][Full Text] [Related]
8. Dosing of factor VIII concentrate by ideal body weight is more accurate in overweight and obese haemophilia A patients.
van Moort I; Preijers T; Hazendonk HCAM; Schutgens REG; Laros-van Gorkom BAP; Nieuwenhuizen L; van der Meer FJM; Fijnvandraat K; Leebeek FWG; Meijer K; Mathôt RAA; Cnossen MH;
Br J Clin Pharmacol; 2021 Jun; 87(6):2602-2613. PubMed ID: 33232535
[TBL] [Abstract][Full Text] [Related]
9. Combining factor VIII levels and thrombin/plasmin generation: A population pharmacokinetic-pharmacodynamic model for patients with haemophilia A.
Bukkems LH; Valke LLFG; Barteling W; Laros-van Gorkom BAP; Blijlevens NMA; Cnossen MH; van Heerde WL; Schols SEM; Mathôt RAA
Br J Clin Pharmacol; 2022 Jun; 88(6):2757-2768. PubMed ID: 34921439
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic profile of children with haemophilia A receiving low-dose FVIII prophylaxis in Indonesia: A single centre experience.
Primacakti F; Sari TT; Gatot D; Sjakti HA; Chozie NA
Haemophilia; 2022 Sep; 28(5):720-725. PubMed ID: 35537097
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A.
Björkman S; Folkesson A; Jönsson S
Eur J Clin Pharmacol; 2009 Oct; 65(10):989-98. PubMed ID: 19557401
[TBL] [Abstract][Full Text] [Related]
12. A comparison of methods for prediction of pharmacokinetics when switching to extended half-life products in hemophilia A patients.
Yu JK; Iorio A; Edginton AN
Thromb Res; 2020 Dec; 196():550-558. PubMed ID: 33157394
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic-guided dosing of factor VIII concentrate in a morbidly obese severe haemophilia A patient undergoing orthopaedic surgery.
Preijers T; Laros-vanGorkom BA; Mathôt RA; Cnossen MH
BMJ Case Rep; 2019 Jan; 12(1):. PubMed ID: 30642854
[TBL] [Abstract][Full Text] [Related]
14. Dose tailoring of human cell line-derived recombinant factor VIII simoctocog alfa: Using a limited sampling strategy in patients with severe haemophilia A.
Delavenne X; Dargaud Y; Ollier E; Négrier C
Br J Clin Pharmacol; 2019 Apr; 85(4):771-781. PubMed ID: 30633808
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic-guided prophylaxis improved clinical outcomes in paediatric patients with severe haemophilia A.
Huang K; Zhen Y; Li G; Wu X; Chen Z; Wu R
Haemophilia; 2021 Jul; 27(4):e450-e457. PubMed ID: 34015176
[TBL] [Abstract][Full Text] [Related]
16. Improvement in clinical outcomes and replacement factor VIII use in patients with haemophilia A after factor VIII pharmacokinetic-guided prophylaxis based on Bayesian models with myPKFiT
Mingot-Castellano ME; Parra R; Núñez R; Martorell M
Haemophilia; 2018 Sep; 24(5):e338-e343. PubMed ID: 30028549
[TBL] [Abstract][Full Text] [Related]
17. Recombinant full-length factor VIII (FVIII) and extended half-life FVIII products in prophylaxis--new insight provided by pharmacokinetic modelling.
Gringeri A; Wolfsegger M; Steinitz KN; Reininger AJ
Haemophilia; 2015 May; 21(3):300-306. PubMed ID: 25643824
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of perioperative FVIII in adult patients with haemophilia A: An external validation and development of an alternative population pharmacokinetic model.
Zhu J; Wu YS; Beechinor RJ; Kemper R; Bukkems LH; Mathôt RAA; Cnossen MH; Gonzalez D; Chen SL; Key NS; Crona DJ
Haemophilia; 2021 Nov; 27(6):974-983. PubMed ID: 34405493
[TBL] [Abstract][Full Text] [Related]
19. Low-dose factor VIII infusion in Chinese adult haemophilia A patients: pharmacokinetics evidence that daily infusion results in higher trough level than with every-other-day infusion with similar factor VIII consumption.
Hua B; Lee A; Fan L; Li K; Zhang Y; Poon MC; Zhao Y
Haemophilia; 2017 May; 23(3):417-421. PubMed ID: 28111886
[TBL] [Abstract][Full Text] [Related]
20. Validation of a perioperative population factor VIII pharmacokinetic model with a large cohort of pediatric hemophilia a patients.
Preijers T; Liesner R; Hazendonk HCAM; Chowdary P; Driessens MHE; Hart DP; Laros-van Gorkom BAP; van der Meer FJM; Meijer K; Fijnvandraat K; Leebeek FWG; Mathôt RAA; Cnossen MH;
Br J Clin Pharmacol; 2021 Nov; 87(11):4408-4420. PubMed ID: 33884664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
